Literature DB >> 16727672

Termination of unwanted pregnancy in dogs with the dopamine agonist, cabergoline, in combination with a synthetic analog of PGF2alpha, either cloprostenol or alphaprostol.

K Onclin1, L D Silva, J P Verstegen.   

Abstract

Associations of a dopamine agonist, cabergoline, and a synthetic analog of PGF2alpha, either alphaprostol or cloprostenol, were used to induce pregnancy termination in 15 mature Beagle bitches. Alphaprostol (20 microg/kg/d) was injected subcutaneously (sc) in combination with cabergoline (1.65 microg/kg/d, sc) daily for 5 d from Day 32 after the LH peak in 5 animals. Cloprostenol 2.5 microg/kg/d in one group (n = 5) and 1 microg/kg/d in another group (n = 5) was also used in combination with the same dosage of cabergoline, following the same protocol, but starting from Day 25 after the LH peak. Treatment efficacy, defined by the number of pregnancy terminations, was 100% in all treated groups. Dose-related side effects due to PGF2alpha were observed (excessive salivation, prostration, vomiting, diarrhoea, scratching at the injection site), and were less severe with cloprostenol than with alphaprostol. In the group treated with the lowest dosage of cloprostenol, no adverse reactions were noticed. In all treated groups, interestrus intervals compared with previous cycles and in control animals were reduced after treatment.

Entities:  

Year:  1995        PMID: 16727672     DOI: 10.1016/0093-691x(95)00024-3

Source DB:  PubMed          Journal:  Theriogenology        ISSN: 0093-691X            Impact factor:   2.740


  2 in total

1.  Prevention of pregnancy in the dog with a combination of prostaglandin F2 alpha and bromocriptine.

Authors:  Colin W Palmer; Klaas Post
Journal:  Can Vet J       Date:  2002-06       Impact factor: 1.008

2.  Progesterone-responsive vaginal leiomyoma and hyperprogesteronemia due to ovarian luteoma in an older bitch.

Authors:  L Ferré-Dolcet; S Romagnoli; T Banzato; L Cavicchioli; R Di Maggio; A Cattai; M Berlanda; M Schrank; A Mollo
Journal:  BMC Vet Res       Date:  2020-08-10       Impact factor: 2.741

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.